Gemelli has been performing commercial EndoZip™ procedures following the system’s CE Mark approval and is now participating as a clinical site in the EASE™ study, which is evaluating EndoZip™ in support of Nitinotes’ U.S. regulatory pathway. The procedures were performed by Prof. Ivo Boskoski, MD, PhD, Associate Professor of Gastroenterology & Digestive Endoscopy at Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in AI-powered digital investigative and intelligence solutions, today announced expanded resources and new leadership for Cellebrite Labs, the team responsible for much of the core mobile research behind the company’s access, extraction and decoding technology. Effective immediately, Cellebrite Labs is operating under the leadership of Chris Wade, Cellebrite’s Chief Technology Officer, and is now part of the company’s Innovation Hub that Wade has led since joining Cellebrite, following its acquisition of Corellium.
Shiv Ramji, Cellebrite’s chief executive officer, said, “Redomiciling is a strategic evolution of our company structure. We believe redomiciling in the U.S. will better position us to drive growth across our key customer segments in our largest geographic market as well as with other large government customers outside of the U.S. Redomiciling will also increase Cellebrite’s appeal across a broader investor pool through inclusion in key indices.”
Aitech, a global leader in AI-powered rugged embedded computing and connectivity solutions for defense and space applications, today announced the C165 Rugged 6U VME Single Board Computer (SBC), helping defense and aerospace organizations build or modernize mission-critical systems while preserving proven VME infrastructure already deployed across air, land, and naval platforms. The C165 enables program teams to modernize computing capabilities within existing systems, extending platform life and accelerating technology refresh efforts without requiring migration to a new architecture.
SUNMI Technology (06810.HK) announced on September 10, separate cooperation agreements with Türkiye-based fintech company TOKEN and Mongolia-based digital bank M bank at the 11th Belt and Road Summit in Hong Kong. The agreements will bring together SUNMI’s commercial IoT and digital commerce capabilities with the partners’ local expertise, advancing collaboration across digital commerce, smart devices, payments, and digital financial services. “Hong Kong is a vital gateway connecting China with global markets,” said Sam, CMO of SUNMI. “Our collaboration with TOKEN and M bank brings SUNMI’s technology together with strong local partners. We look forward to working with more partners across Eurasia to make digitalization more accessible to businesses in every market.”
Arasan Chip Systems announces its participation in the I3C® Interoperability Session to be held at the sidelines of the Member Meeting in Taipei. Arasan will test its I3C® Host IP, I3C® Dual Mode IP (supports I3C® Host & Device) and I3C® Device IP with other I3C® interop participants. Arasan will also test its licensable proprietary I3C® software stack.
Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that the Company plans to participate in two upcoming investor events later this month. Date:September 10, 2026Conference:Lake Street 10th Annual Best Ideas Growth ConferenceFormat: One-on-One Meetings OnlyEvent URL: https://investors.cellebrite.com/events/event-details/lake-street-10th-annual-best-ideas-growth-conference Cellebrite executives: Andrew Kramer, vice president, investor relations & treasuryDate:September 14, 2026Event:Cellebrite Virtual Fireside Chat Overview: Learn more about the opportunity ahead for Cellebrite, including an overview of the Company’s AI strategy and key product roadmapsPresentation Time:4:15 p.m. ETFormat: Webcast Event URL: https://investors.cellebrite.com/events/event-details/cellebrite-virtual-fireside-chat Webcast URL: https://event.summitcast.com/view/R68kZxMQty7nPH4h3TQBD5/L7r7NZ6hEKUJU6rXQy4u3g Moderated by: Rudy Kessinger, D.A. Davidson & Co.Cellebrite executives: Shiven Ramji, chief executive officer David Barter, chief financial officerChristopher Wade, chief technology
Guardian has completed an assessment under the Infosec Registered Assessors Program (IRAP) at the PROTECTED classification level. The assessment was conducted by CyberCX, an Australian Signals Directorate (ASD)-endorsed IRAP assessor. For the Australian law enforcement, public safety, correctional, defense and national security agencies Guardian will serve, the assessment is about more than a compliance milestone. Digital evidence — a phone extraction tied to a missing child case, cloud footage from a border incident or records supporting a counterterrorism investigation — is often the difference between a case that closes and one that stalls. Agencies need to move that evidence to the cloud to securely collaborate faster across investigators, prosecutors and partner agencies, and the IRAP assessment gives Australian agencies independent, documented assurance that Guardian can carry that sensitive workload without compromising security.
Lying neither along the border nor by the sea, how does inland Hunan forge an open corridor linking itself to Africa? Explore how the Hunan model promotes China-Africa economic and trade cooperation.
Achieving CMMC Level 2 certification is a significant milestone for CFSI and another clear signal to our federal customers and partners that the protection of their most sensitive information is paramount,” said Philip O’Reilly, senior vice president, chief operating officer and head of federal strategy for Cellebrite Federal Solutions. “This independent, third-party validation — alongside our recent FedRAMP High authorization— reflects our ongoing commitment to conducting business with the federal government in a trusted, secure and responsible manner. As the Department of War moves the entire industry toward mandatory third-party assessment, CFSI is proud to be ahead of the curve, putting us in the top 3% of organizations that have met the standard.”
As digital devices increasingly shape the course of modern conflict, the intelligence they hold is now critical to a mission, revealing locations, connections and operational plans. However, this intelligence has a short half-life. When a military unit has only minutes to complete a mission, the value of digital data can be lost if the device isn’t extracted on the spot. Mission-critical data and intelligence are lost or an enemy battlefield advantage gained. Furthermore, sending devices to a lab and waiting days or months for analysis often means the information may be outdated and unusable by the time it is returned.
The capital raise supports ongoing Phase 2b/3 clinical trial for prevention of bronchopulmonary dysplasia and associated CMC and analytical activities. Approximately 94% of existing investors participated in the Series E-2 round. Interim analysis completing the Phase 2b portion of the trial expected by the end of Q2 2027.
A delegation of 55 young media representatives from seven African countries recently visited central China’s Hunan Province to explore new opportunities for practical cooperation between China and Africa. They visited various enterprises, learned about the region’s development achievements, and immersed themselves in Chinese culture. The representatives highlighted the potential for cooperation in industrial, cultural, media, green energy, and agricultural sectors.
Cellebrite Genesis is now generally available for enterprise organizations, expanding to more global markets. The AI-powered solution has seen significant user growth worldwide, serving a mix of national, regional, and local agencies. Genesis helps corporate investigations move from manual evidence review to AI-assisted investigation, accelerating the speed and efficacy of investigations across various crime types. Examples include averting a planned school shooting, protecting children from predators, and converting prison conversations into actionable intelligence.
Prodigy Technovations Pvt. Ltd, a leader in protocol analysis solutions, proudly announces the successful testing and launch of the PGY-UFS5-EX-PA. This groundbreaking tool is the industry’s first UFS 5.0 protocol exerciser and analyzer designed to accelerate the development of next-generation flash memory interfaces required for the burgeoning AI-driven ecosystem. Supporting MIPI M-PHY® v6.0, MIPI UniPro® v3.0, and the JEDEC UFS 5.0 specification, the PGY-UFS5-EX-PA enables data transfer rates of 46.64Gbps per lane. This massive leap in throughput is critical for the seamless execution of artificial intelligence (AI) workloads, high-speed mobile computing, automotive ADAS, and immersive AR/VR applications.
“The new SOSA-aligned U-C6850 Ethernet Switch provides the high-speed networking backbone needed to connect compute resources, sensors and communications systems while supporting the Modular Open Systems Approach (MOSA) architectures defense customers need,” said Alex Trigoub, product manager, Aitech. “By enabling seamless integration into open architectures, the U-C6850 helps customers modernize legacy platforms with advanced networking technology, accelerate technology insertion and reduce lifecycle risks associated with proprietary systems.”
The milestone was marked by the completion of the first study procedure at the institutions by Reem Z. Sharaiha, MD, Professor of Medicine at Weill Cornell Medicine and Director of Endoscopy at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. The EASE™ IDE trial is evaluating the safety and effectiveness of the EndoZip™ Endoscopic Suturing System for performing Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive endoscopic procedure for the treatment of obesity.
Neurolief, a neuroscience-driven medical technology company, is bringing two prescription therapies to U.S. veterans through a new Department of Veterans Affairs contract. Proliv®Rx for major depressive disorder and Relivion®MG for migraine are now available for veterans, expanding access to non-invasive, physician-supervised neuromodulation therapy at home. This initiative aims to provide effective treatment for veterans who face barriers to frequent in-clinic visits, including those in rural and underserved areas.
“Andromeda’s customers can now access a dedicated NeuralMesh or a GPU-native WEKA NeuralMesh Axon deployment to achieve consistent storage performance across any cluster running on any hyperscaler or AI cloud. Keeping GPUs Fed Across Every Environment.”
“I am honored to join the Continuity Biosciences Board of Directors at such a pivotal time in the Company’s development,” said Papoutsis. “Continuity has assembled an outstanding management team, scientific advisors, and Board while building an innovative portfolio of precision drug delivery technologies across multiple therapeutic areas. I look forward to supporting the Company’s long-term strategy, helping expand its strategic partnerships, and contributing to its missions of improving outcomes for patients.”